United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News Why did Amgen Inc. walk away from its $1.25bn eczema drug deal with Kyowa Kirin? Amgen Inc. exits its $1.25B eczema drug deal with Kyowa Kirin Co., Ltd., reshaping its immunology focus. Find out what this move means for both companies’ pipelines. byPallavi MadhirajuJanuary 31, 2026